Payment overview · 2025
General Payments
$223.24
10 reported records · 7 companies
Healthcare provider profile · identity verified
Michael B Jacobs, M.D., PH.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LAS VEGAS, NV · NPI 1053300913
Verified facts
What the public records show
CMS Open Payments records show Michael B Jacobs, M.D., PH.D. received $223.24 in general payments during 2025 across 10 reported records.
Amgen Inc. accounted for 24.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $53.63 | 24.0% | 2 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $43.33 | 19.4% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $41.53 | 18.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.25 | 14.4% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $20.05 | 9.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.34 | 7.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.11 | 6.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $223.24 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $53.63 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $53.63 | 2 | 2025 |
Source payment records
|
|||||
| Hillrom - Volara System Normalized: hillrom volara system |
Device | Baxter Healthcare | $43.33 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $41.53 | 2 | 2025 |
Source payment records
|
|||||
| inCourage Airway Clearance Therapy Normalized: incourage airway clearance therapy |
Device | Philips North America LLC | $20.05 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.70 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.34 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.34 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.11 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 273 | 86 |
| Levothyroxine Sodium | Levothyroxine Sodium | 145 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 133 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 109 | 36 |
| Amlodipine Besylate | Amlodipine Besylate | 103 | 29 |
| Metformin Hcl | Metformin Hcl | 101 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 98 | 29 |
| Furosemide | Furosemide | 81 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 81 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 75 | 29 |
| Ipratropium Bromide | Ipratropium Bromide | 71 | 29 |
| Trazodone Hcl | Trazodone Hcl | 69 | 13 |
| Gabapentin | Gabapentin | 65 | 26 |
| Lisinopril | Lisinopril | 64 | 20 |
| Losartan Potassium | Losartan Potassium | 61 | 22 |
| Spironolactone | Spironolactone | 58 | 19 |
| Ozempic | Semaglutide | 57 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 56 | 15 |
| Famotidine | Famotidine | 56 | 17 |
| Methylprednisolone | Methylprednisolone | 53 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 50 | 17 |
| Montelukast Sodium | Montelukast Sodium | 50 | 16 |
| Omeprazole | Omeprazole | 49 | 24 |
| Donepezil Hcl | Donepezil Hcl | 48 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 19 |
| Prednisone | Prednisone | 43 | 20 |
| Eliquis | Apixaban | 40 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 39 | suppressed |
| Allopurinol | Allopurinol | 38 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 38 | 17 |
| Simvastatin | Simvastatin | 36 | suppressed |
| Carvedilol | Carvedilol | 34 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 33 | 11 |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 30 | suppressed |
| Glimepiride | Glimepiride | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Alprazolam | Alprazolam | 26 | suppressed |
| Ketoconazole | Ketoconazole | 26 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Vascepa | Icosapent Ethyl | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 19 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 15 |
| Brilinta | Ticagrelor | 17 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 16 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $223.24 · 10 records | Amgen Inc. | Cologuard Collection Kit, Hillrom - Volara System, MOUNJARO, NUPLAZID, OTEZLA, REPATHA, The Cologuard Plus Collection Kit, XIFAXAN, ZEPBOUND, inCourage Airway Clearance Therapy | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error